Compare Appian Corp (APPN) vs Smith & Nephew plc (SNN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Appian Corp vs Smith & Nephew plc — how do they compare? Appian Corp trades at $25.5 (market cap $1.86B), while Smith & Nephew plc trades at $30.7 (market cap $12.69B). The key difference: Smith & Nephew plc is far larger — about 6.8× Appian Corp's market cap, and Smith & Nephew plc pays a 2.55% dividend while Appian Corp pays none. Which is the better fit depends on your goals.
| APPN | SNN | |
|---|---|---|
Market Cap | $1.86B | $12.69B |
Sector | Technology | Health |
52-Week High | $45.64 | $38.70 |
52-Week Low | $18.72 | $28.73 |
Enterprise Value | $1.95B | $15.46B |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Appian (APPN) trades at $25.36, up 0.48% on the day, with a bullish technical signal from moving averages and a consensus price target of $26.20. The company reported positive net income in 2025 after years of losses, with revenue growing to $726.94M and operating cash flow improving to $62.87M. Recent news highlights focus on AI strategy and enterprise adoption, though the CEO's share sale and negative shareholder equity present mixed signals.
The outlook is cautiously optimistic with revenue growth and cash flow recovery, but risks include high debt levels, negative equity, and intense competition. Analyst sentiment is mixed with a majority Hold rating. The stock offers potential from AI-driven growth but requires monitoring of profitability sustainability and balance sheet health.
Smith & Nephew (SNN) trades at $30.70, up 0.99% with a bullish technical signal supported by moving averages. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B (2024-2025) and net income margin expanding to 10.14%. Recent developments include new medical guidance publications and robotics platform advancements, while analyst consensus remains cautious with 68% hold ratings.
SNN presents a mixed outlook with strong profitability metrics and positive cash flow trends offset by recent earnings misses and conservative analyst sentiment. Investment opportunity lies in the company's medical technology innovations and margin expansion, though risks include competitive pressures and execution challenges in meeting growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
